Experimental findings reveal that STAT5 hyperactivation increases autophagy in B-ALL, suggesting new therapeutic strategies with ruxolitinib and imatinib.
Key Points
Investigate the role of STAT5-signaling in acute lymphoblastic leukemia and its therapeutic implications.
Model STAT5 signaling thresholds using gain- and loss-of-function mutations.
Conduct metabolomic and lipidomic analyses of leukemia cells.
Utilize xenograft models to study treatment effects of STAT5-agonists and tyrosine kinase inhibitors.
STAT5 hyperactivation enhanced autophagy and prolonged survival in B-ALL xenografts.
Inhibitors ruxolitinib and imatinib suppressed STAT5 activity, reducing proliferation.
A combination of MYC and BCL6 modulation indicated a novel therapeutic approach.